Name | (2S,3S,4S,5R,6S)-6-[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-7-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid |
---|---|
Synonyms |
Scutellarein-7beta-D-glucuronoside
Breviscapine 4H-1-Benzopyran-4-one, 7-(β-D-glucopyranuronosyloxy)-5,6-dihydroxy-2-(4-hydroxyphenyl)-, compd. with 7-[(5ξ)-β-D-xylo-hexopyranuronosyloxy]-5-hydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one ( 1:1) Scutellarein-7-glucuronide 5,6-Dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl β-D-glucopyranosiduronic acid - 5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl (5ξ)-β-D-xylo-hexopyranosiduronic acid (1:1) Breviscapin 5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4h-chromen-7-yl |A-d-glucopyranosiduronic acid Scutellarein-7beta-D-glucuronide |
Description | Breviscapine is a crude flavonoid extract of Breviscapine, which is more than 85% of the active ingredient, Breviscapine. Breviscapine has a wide range of cardiovascular pharmacological activities, such as increasing blood flow, improving microcirculation, dilating blood vessels, reducing blood viscosity, promoting fibrinolysis, inhibiting platelet aggregation and thrombosis. Breviscapine has been used in the study of cerebral infarction and its sequelae, cerebral thrombosis, coronary heart disease and angina pectoris[1][2]. |
---|---|
Related Catalog | |
References |
Density | 1.81g/cm3 |
---|---|
Boiling Point | 891.6ºC at 760mmHg |
Molecular Formula | C54H84N16O21 |
Molecular Weight | 1293.34 |
Flash Point | 314.9ºC |
Exact Mass | 908.164734 |
PSA | 394.47000 |
Vapour Pressure | 3.91E-34mmHg at 25°C |
Index of Refraction | 1.763 |
Storage condition | 2-8°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|